FDA Signs Confidentiality Commitment with Indonesia

Today, the U.S. Food and Drug Administration (FDA) signed a confidentiality commitment (CC) with the Fish Quarantine and Inspection Agency (FQIA) of the Ministry of Marine Affairs and Fisheries of the Republic of Indonesia.

The CC will allow for the exchange of confidential information, including inspection records, sample findings, and other nonpublic documents, and is an important step in preparing Indonesia for participation in a three-country pilot program designed to ensure the safety of shrimp exported to the United States.

In FY 2021, 2022 and 2023, Congress mandated that FDA develop and implement options for regulating shrimp imports, including imports from the three largest exporting countries by volume over the previous three calendar years. Currently, these countries are India, Indonesia, and Ecuador, respectively.

The FDA is preparing to evaluate the effectiveness of using a new form of arrangement — a Regulatory Partnership — in these countries. The partnership aims to leverage commodity-specific oversight systems — in this case, involving shrimp — along with data and information, to strengthen food safety before and at the port of entry.

Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy, signed the CC on behalf of the FDA. Dr. Pamuji Lestari, Director General of FQIA, signed the CC on behalf of FQIA.

“This Partnership will be mutually beneficial to both our countries,” Mr. Abdoo said from Washington, D.C., during a virtual signing ceremony with FQIA. “Together, as partners, this confidentiality commitment will help us both determine how we can most effectively collaborate to enhance our regulatory efforts on shrimp safety. We look forward to more activities together in the future.”

###